Full Text
Evaluating The Annual Cost Per Response Rate of Pirfenidone And Nintedanib For The Treatment of Patients With Idiopathic Pulmonary Fibrosis

Abstract

Authors

L Papageorgiou A Skroumpelos K Samara X Caporis

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×